Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Isosorbide-mononitrate does not offer protection against first variceal bleeding in patients with cirrhosis

In the prevention of the first variceal bleeding in cirrhotic patients with ascites, nadolol is superior to isosorbide mononitrate, finds a study in the September issue of the Journal of Hepatology.

News image

fiogf49gjkf04

Variceal bleeding is a common and often severe complication in patients with cirrhosis and portal hypertension.

Once such bleeding occurs it is a high resource-consuming event that is associated with a high mortality rate, which in the most recent series has approached 25%.

β-blockers have been shown to effectively prevent first variceal bleeding (FVB) in cirrhotic patients. However, these drugs are not effective in the treatment of all patients.

The addition of isosorbide-mononitrate (Is-Mn) to non-selective β-blockers has therefore been suggested to improve the clinical efficacy of these drugs.

This combined therapy promotes a greater reduction in portal pressure, almost double that which can be achieved with the use of β-blockers alone.

Several studies have strongly suggested that this combined therapy is the treatment of choice for the secondary prevention of variceal bleeding.

In the treatment of primary variceal bleeding, however, the evidence supporting the use of β-blockers and Is-Mn in combination is controversial.

A combined analysis of 3 separate studies, involving 522 patients, found no significant differences in the prevention of first bleeding and mortality between patients administered the combination therapy, or those given β-blockers alone.

Furthermore, in some patients with ascites, the use of β-blockers can be precluded by the high rate of contraindications and side effects.

In this situation, Is-Mn alone, with its ability to reduce portal hypertension as a long-acting vasodilator, has been put forward as an alternative to β-blockers in the prevention of FVB.

Researchers in Italy have therefore compared the efficacy and applicability of nadolol and isosorbide-mononitrate in preventing FVB in a population of cirrhotic patients at high risk of variceal bleeding with ascites, who can be frequently intolerant to β-blockers.

A total of 80 consecutive cirrhotic patients with ascites and esophageal varices (25% average risk of bleeding at 1 year) were considered.

28 of these patients were excluded from taking further part in the study due to contraindications, and the remaining 52 were randomly assigned to receive either nadolol (n = 25) or Is-Mn (n = 27).

Is-Mn - offers no protection against FVB in cirrhotic patients
Journal of Hepatology

The researchers found the frequency of contraindications was greater for β-blockers than Is-Mn (35% versus 0%).

During 21.3 ±11.6 months of follow-up, side effects forced 6 patients taking nadolol and 4 taking Is-Mn to stop treatment.

Bleeding occurred in 2 patients taking nadolol and 10 taking Is-Mn.

The probability of bleeding was significantly lower in the nadolol group whereas overall survival was similar between both groups. A total of 7 patients on Is-Mn and 8 on nadolol died.

Dr Gianmario Borroni, one of the authors of the report, commented that, perversely, in patients with ascites, Is-Mn is tolerated but ineffective while nadolol is effective but less tolerated.

In an accompanying editorial on the alternatives to non-selective β-blockers in the treatment of FVB in the same issue of the journal, Dr Juan Carlos Garcia-Pagan said that the study by Borroni et al. "clearly showed that Is-Mn does not offer any protection against first variceal bleeding in patients with cirrhosis."

J Hepatol 2002; 37(3): 315-321
16 August 2002

Go to top of page Email this page Email this page to a colleague

 19 January 2018 
Ileoanal pouch microbiota
 19 January 2018 
Predicting the risk of early surgery in Crohn’s
 19 January 2018 
Lifestyle intervention vs gastric bypass for obesity and diabetes
 18 January 2018 
Sleeve gastrectomy vs Roux-en-Y gastric bypass
 18 January 2018 
Healthcare costs of liver cancer in the USA
 18 January 2018 
High-risk adenomas at colonoscopy
 17 January 2018 
“Weekend effect” in upper GI hemorrhage
 17 January 2018 
Gut dysbiosis and non-antibiotic prescription medications
 17 January 2018 
Reducing surgical infections in high-outlier colorectal unit
 16 January 2018 
Bundle of care in GI cancer surgery
 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 15 January 2018 
Risks of death after liver transplants for liver cancer
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 22 December 2017 
Colonoscopy after colorectal cancer resection
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
Health management for IBD
 21 December 2017 
PPI and Alzheimer's disease
 20 December 2017 
Management of abnormal liver blood tests
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 13 December 2017 
Disease severity in NAFLD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us